|
Video: What is a Stock Split?
|
|
Shattuck Labs is a clinical-stage biopharmaceutical company engaged in developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint and GADLEN platforms, as classes of biologic medicines capable of multifunctional activity with applications in oncology and inflammatory diseases. Co.'s product candidate SL-172154, which is in Phase 1 clinical trial for the treatment of patients with ovarian cancer. Co.'s second product candidate, SL-279252, which is developed to inhibit the PD-1/PD-L1 interaction and activate the OX40 costimulatory receptor and is in Phase 1 clinical trial in patients with solid tumors and lymphoma. Co. has several compounds in preclinical development. According to our STTK split history records, Shattuck Labs has had 0 splits. | |
|
Shattuck Labs (STTK) has 0 splits in our STTK split history database.
Looking at the STTK split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Shattuck Labs shares, starting with a $10,000 purchase of STTK, presented on a split-history-adjusted basis factoring in the complete STTK split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/09/2020 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$19.35 |
|
End price/share: |
$8.94 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-53.80% |
|
Average Annual Total Return: |
-19.96% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,619.78 |
|
Years: |
3.47 |
|
|
|
|
|